Published in Diabetes Care on January 01, 2014
Epidemiology of Diabetes Interventions and Complications (EDIC) | NCT00360893
Diabetes Control and Complications Trial (DCCT) | NCT00360815
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04
Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int (2014) 0.94
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context (2014) 0.89
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving! Diabetes Care (2014) 0.86
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options. Clin Interv Aging (2014) 0.85
Diabetes Dyslipidemia. Diabetes Ther (2016) 0.85
Risk Factors for Cardiovascular Disease in Type 1 Diabetes. Diabetes (2016) 0.83
Examining Dose of Diabetes Group Medical Visits and Characteristics of the Uninsured. West J Nurs Res (2014) 0.82
BP Control and Long-Term Risk of ESRD and Mortality. J Am Soc Nephrol (2016) 0.81
Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis. Cardiovasc Diabetol (2016) 0.81
Uncomplicating the Macrovascular Complications of Diabetes: The 2014 Edwin Bierman Award Lecture. Diabetes (2015) 0.81
Altered platelets' morphological parameters in children with type 1 diabetes – a case-control study. BMC Endocr Disord (2015) 0.80
Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care (2016) 0.78
Lipoprotein subfraction cholesterol distribution is more atherogenic in insulin resistant adolescents with type 1 diabetes. Pediatr Diabetes (2015) 0.77
Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res (2015) 0.76
Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes. Am J Med Sci (2016) 0.76
The pecking order of skin Advanced Glycation Endproducts (AGEs) as long-term markers of glycemic damage and risk factors for micro- and subclinical macrovascular disease progression in Type 1 diabetes. Glycoconj J (2016) 0.75
Does Rapid Diffusion of HbA1c Testing Affect Amputation Rates? Vasc Endovascular Surg (2016) 0.75
Testosterone and cardiac mass and function in men with type 1 diabetes in the Epidemiology of Diabetes Interventions and Complications Study (EDIC). Clin Endocrinol (Oxf) (2016) 0.75
My Sweetheart Is Broken: Role of Glucose in Diabetic Cardiomyopathy. Diabetes Metab J (2017) 0.75
Associations among glycemic excursions, glycated hemoglobin and high-sensitivity C-reactive protein in patients with poorly controlled type 2 diabetes mellitus. Exp Ther Med (2015) 0.75
Impact of Long-Term Poor and Good Glycemic Control on Metabolomics Alterations in Type 1 Diabetic People. J Clin Endocrinol Metab (2016) 0.75
Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease. Diabetes Ther (2016) 0.75
Consistency of Hemoglobin A1c Testing and Cardiovascular Outcomes in Medicare Patients With Diabetes. J Am Heart Assoc (2016) 0.75
Protocol for systematic review of evidence on the determinants and influence of early glycaemic control in childhood-onset type 1 diabetes. Syst Rev (2015) 0.75
Diabetes: Cardiovascular benefits of metformin in T1DM. Nat Rev Endocrinol (2017) 0.75
Cohort Profile: Scottish Diabetes Research Network Type 1 Bioresource Study (SDRNT1BIO). Int J Epidemiol (2016) 0.75
The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care (2017) 0.75
Association between fasting glucose and all-cause mortality according to sex and age: a prospective cohort study. Sci Rep (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med (2003) 5.87
Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol (1995) 4.83
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
Type 1 diabetes and coronary artery disease. Diabetes Care (2006) 2.47
Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation (2011) 1.20
Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res (2012) 1.01
When are type 1 diabetic patients at risk for cardiovascular disease? Curr Diab Rep (2010) 1.00
Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes (2013) 0.96
Aortic distensibility in type 1 diabetes. Diabetes Care (2013) 0.93
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med (2005) 27.77
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med (2009) 12.15
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med (2000) 10.05
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care (2012) 7.83
TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med (2006) 7.75
A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med (2012) 7.51
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet (2010) 6.66
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care (2002) 3.96
Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol (2008) 3.83
A controlled trial of web-based diabetes disease management: the MGH diabetes primary care improvement project. Diabetes Care (2003) 3.57
Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA (2003) 3.33
Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care (2008) 3.33
The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes (2003) 3.23
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes. Diabetes (2009) 3.16
Tests of glycemia for the diagnosis of type 2 diabetes mellitus. Ann Intern Med (2002) 3.06
Tests of glycemia in diabetes. Diabetes Care (2004) 3.03
The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes (2006) 3.00
Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab (2006) 2.98
Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care (2012) 2.90
Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med (2009) 2.88
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem (2011) 2.82
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes (2005) 2.80
Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes (2003) 2.76
Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 2.75
Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care (2006) 2.64
Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes (2008) 2.60
Translating the chronic care model into the community: results from a randomized controlled trial of a multifaceted diabetes care intervention. Diabetes Care (2006) 2.59
Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med (2017) 2.56
Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus. Circulation (2005) 2.46
Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care (2005) 2.45
Detailed physiologic characterization reveals diverse mechanisms for novel genetic Loci regulating glucose and insulin metabolism in humans. Diabetes (2010) 2.44
Influence of health care providers on the development of diabetes complications: long-term follow-up from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care (2002) 2.35
The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab (2008) 2.27
Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol (2006) 2.25
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Comparison of hyperglycemia, hypertension, and hypercholesterolemia management in patients with type 2 diabetes. Am J Med (2002) 2.19
Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol (2010) 2.17
Psychological predictors of physical activity in the diabetes prevention program. J Am Diet Assoc (2006) 2.13
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care (2014) 2.04
A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes (2004) 2.03
Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab (2008) 2.03
Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation (2005) 2.02
Rapid identification of myocardial infarction risk associated with diabetes medications using electronic medical records. Diabetes Care (2009) 2.00
A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care (2012) 1.97
Sexual dysfunction in women with type 1 diabetes: long-term findings from the DCCT/ EDIC study cohort. Diabetes Care (2009) 1.87
A controlled trial of population management: diabetes mellitus: putting evidence into practice (DM-PEP). Diabetes Care (2004) 1.85
The relationship of fasting serum radioimmune insulin levels to incident coronary heart disease in an insulin-treated diabetic cohort. J Clin Endocrinol Metab (2004) 1.84
Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes (2014) 1.81
Improvements in the life expectancy of type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications study cohort. Diabetes (2012) 1.79
New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet (2012) 1.79
Tests of glycemia in diabetes. Diabetes Care (2003) 1.79
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One (2012) 1.74
The hemoglobin glycation index is not an independent predictor of the risk of microvascular complications in the Diabetes Control and Complications Trial. Diabetes (2007) 1.73
A genome-wide association search for type 2 diabetes genes in African Americans. PLoS One (2012) 1.72
Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care (2011) 1.71
Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study. PLoS Genet (2008) 1.67
Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab (2011) 1.63
Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes (2008) 1.62
Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes (2010) 1.60
Prevalence of hyper- and hypoglycemia among inpatients with diabetes: a national survey of 44 U.S. hospitals. Diabetes Care (2007) 1.57
Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes. Diabetes (2008) 1.56
Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clin Trials (2012) 1.54
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology (2008) 1.53
Randomized controlled community-based nutrition and exercise intervention improves glycemia and cardiovascular risk factors in type 2 diabetic patients in rural Costa Rica. Diabetes Care (2003) 1.53
Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes (2007) 1.51
Lifestyle intervention is associated with lower prevalence of urinary incontinence: the Diabetes Prevention Program. Diabetes Care (2006) 1.50
High-density lipoprotein cholesterol in diabetes: is higher always better? J Clin Lipidol (2011) 1.50
Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab (2007) 1.49
Adiponectin: good, bad, or just plain ugly? Kidney Int (2008) 1.48
Pulse wave analysis and cardiac autonomic neuropathy in type 1 diabetes: a report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Technol Ther (2011) 1.48
Psychological and behavioral correlates of baseline BMI in the diabetes prevention program (DPP). Diabetes Care (2002) 1.48
Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care (2014) 1.47
Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. Diabetes (2006) 1.46
Developing and validating a diabetes database in a large health system. Diabetes Res Clin Pract (2006) 1.46
Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study. Diabetes Care (2007) 1.46